Block Listing 6 Monthly Return

RNS Number : 1728U

Shield Therapeutics PLC

31 March 2021

 

Shield Therapeutics plc

("Shield" or the "Group")

Block Listing 6 Monthly Return

Date: 31 March 2021

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		S hield Therapeutics Retention Share Plan
Period of return:	From:	01 October 2020	To:	31 March 2021
Balance of unallotted securities under scheme(s) from previous return:		54,219
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		-14,425
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		39,794

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan
Period of return:	From:	01 October 2020	To:	31 March 2021
Balance of unallotted securities under scheme(s) from previous return:		388,079
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		388,079

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan
Period of return:	From:	01 October 2020	To:	31 March 2021
Balance of unallotted securities under scheme(s) from previous return:		171,883
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		-147,610
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		24,273

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan
Period of return:	From:	01 October 2020	To:	31 March 2021
Balance of unallotted securities under scheme(s) from previous return:		1,885,819
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		2,500,000*
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		-1,207,543
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		3,178,276

*Please note this number is further to the block listing applied for on the 24^th March 2021 and admitted on 30^th March 2021. This block listing has been allocated to the Shield Therapeutics Retention and Performance Share Plan in entirety.

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	[phone]

For further information, please contact:

Shield Therapeutics plc	[phone]
Tim Watts (CEO) Lucy Huntington-Bailey, (Company Secretary and General Counsel)
Peel Hunt LLP - Nominated Adviser & Joint Broker			[phone]
James Steel / Christopher Golden
finnCap Ltd - Joint Broker	[phone]
Geoff Nash / Alice Lane / Matthew Radley
Walbrook PR - Financial PR & IR Adviser		[phone]
Paul McManus / Lianne Cawthorne	or [e-mail]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

BLREADDFDSEFEFA